Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety assessment of nicotinamide mononucleotide (NMN) in healthy volunteers
jRCTs041200034Completed
- Sponsor
- Mitsubishi Corporation
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial comparing NMN 250 mg/day with Placebo (2 arms). Primary endpoints: Safety assessment via physical measurements, Safety assessment via hematology and 3 more. Started Feb 2021; status: completed.
02
Drugs
nicotinamide mononucleotide
Beyond the preview
Go deeper on jRCTs041200034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200034.